UBS analyst Ashwani Verma initiated coverage of Corcept Therapeutics (CORT) with a Neutral rating and $95 price target The firm cites valuation for the Neutral rating with the shares up 75% year-to-date. The stock is already pricing in both the continued growth in hypercortisolism and Corcept’s new launch opportunity in platinum-resistant ovarian cancer, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Hold Rating for Corcept Therapeutics Amid Limited Upside and Market Challenges
- 3 ‘Strong Buy’ Stocks to Buy Today, 12/9/2025, According to Top Analysts
- 3 ‘Strong Buy’ Stocks Backed by Technical Analysis
- Corcept Therapeutics: Poised for Growth with Relacorilant’s Launch and Strong Market Positioning
- Corcept Therapeutics initiated with a Peer Perform at Wolfe Research